Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine. Medical records of dogs with a diagnosis of HS that...

Author(s)
Mason, S. L.; Finotello, R.; Blackwood, L.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 1, pp E30-E37
Abstract

The nitrosourea drug lomustine is used clinically for treating a wide variety of malignancies, most commonly brain tumors and lymphoma. Lomustine undergoes hydrolysis in vivo to form isomeric metabolites, primarily trans-4-hydroxylomustine (trans-4) and cis-4-hydroxylomustine (cis-4) in various...

Author(s)
Chakkath, T.; Lavergne, S. N.; Fan, T. M.; Bunick, D.; Dirikolu, L.
Publisher
MDPI AG, Basel, Switzerland
Citation
Veterinary Sciences, 2014, 1, 3, pp 159-173
Abstract

Background: Compounded lomustine is used commonly in veterinary patients. However, the potential variability in these formulations is unknown and concern exists that compounded formulations of drugs may differ in potency from Food and Drug Administration (FDA)-approved products....

Author(s)
Burton, J. H.; Stanley, S. D.; Knych, H. K.; Rodriguez, C. O.; Skorupski, K. A.; Rebhun, R. B.
Publisher
Wiley-Blackwell, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2016, 30, 1, pp 242-246
Abstract

Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL). All patients responded to either...

Author(s)
Elliott, J.; Baines, S.
Publisher
Wiley, Melbourne, Australia
Citation
Australian Veterinary Journal, 2019, 97, 9, pp 308-315
Abstract

The efficacy and toxicity of lomustine and prednisone for treating high-grade completely excised mast cell tumors (MCTs) was evaluated in a retrospective study of 15 dogs. Dogs were treated with lomustine (CCNU) at 70 mg/m2 every 4 weeks and prednisone at 0.5 to 1 mg/kg body weight PO daily. Eight ...

Author(s)
Hay, J. K.; Larson, V. S.
Publisher
Canadian Veterinary Medical Association, Ottawa, Canada
Citation
Canadian Veterinary Journal, 2019, 60, 12, pp 1326-1330
Abstract

Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments. The efficacies of various treatment modalities for canine brain tumours have been previously described, though little data...

Author(s)
Moirano, S. J.; Dewey, C. W.; Wright, K. Z.; Cohen, P. W.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 4, pp 459-466
Abstract

Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies...

Author(s)
Morgan, E.; O'Connell, K.; Thomson, M.; Griffin, A.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 4, pp 622-629
Abstract

DNA Alkylation is thought to be the reason for the efficacy of lomustine while carbamylation has been implicated as the cause for the side effects seen with lomustine treatment such as hepatotoxicity. In the alkylation study we show that lomustine and its metabolites form similar levels of the DNA...

Author(s)
Chakkath, T.; Lavergne, S.; Fan, T. M.; Bunick, D.; Dirikolu, L.
Publisher
MDPI AG, Basel, Switzerland
Citation
Veterinary Sciences, 2015, 2, 2, pp 52-68
Abstract

The purpose of this present study was to objectively evaluate gastrointestinal and bone marrow AEs after administration of various chemotherapeutic agents in canines with malignant tumors, using the Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE),...

Author(s)
Ji NaNi; Song JoongHyun; Hwang TaeSung; Lee HeeChun; Yu DoHyeon; Jung DongIn
Publisher
Korean Society of Veterinary Clinics, Seoul, Korea Republic
Citation
Journal of Veterinary Clinics, 2019, 36, 1, pp 30-37
Abstract

Canine histiocytic sarcoma (HS) is an aggressive tumor type originating from dendritic cells or macrophages. We previously reported high incidence of the two-base (AT) insertion mutation (insAT) in the tumor protein p53 (TP53) gene in dogs with HS, and the aim of this study was to investigate the...

Author(s)
Asada, H.; Tomiyasu, H.; Okada, K.; Chambers, J. K.; Goto-Koshino, Y.; Uchida, K.; Kagawa, Y.; Ohno, K.; Tsujimoto, H.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Research in Veterinary Science, 2019, 124, pp 57-60

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics